Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Haemonetics Corporation (NYSE:HAE) has received a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $84.40.

HAE has been the subject of a number of analyst reports. Raymond James Financial reissued an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. Weiss Ratings restated a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. CJS Securities raised Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Barrington Research boosted their price target on Haemonetics from $90.00 to $93.00 and gave the company an “outperform” rating in a research note on Monday, January 12th. Finally, Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th.

Institutional Investors Weigh In On Haemonetics

A number of large investors have recently bought and sold shares of the stock. True Wealth Design LLC lifted its position in Haemonetics by 6,700.0% in the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 335 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 165 shares in the last quarter. Versant Capital Management Inc boosted its position in shares of Haemonetics by 216.4% during the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 567 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Haemonetics by 20,925.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 837 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Trading Down 1.7%

NYSE HAE opened at $68.84 on Friday. The firm has a market capitalization of $3.22 billion, a PE ratio of 20.13, a price-to-earnings-growth ratio of 1.43 and a beta of 0.29. The business’s 50-day moving average price is $79.33 and its two-hundred day moving average price is $65.78. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The company had revenue of $327.32 million for the quarter, compared to analyst estimates of $311.61 million. During the same period in the previous year, the firm earned $1.12 earnings per share. The firm’s quarterly revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, analysts expect that Haemonetics will post 4.55 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.